aTyr Pharma Inc.
3545 John Hopkins Road, Suite 250
San Diego
California
92121
United States
258 articles about aTyr Pharma Inc.
-
aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2021 Financial ResultsManagement to host conference call and webcast on November 10th at 5:00 pm EST / 2:00 pm PST
11/3/2021
aTyr Pharma, Inc. today announced that it will report third quarter 2021 financial results and provide a corporate update after the market close on Wednesday, November 10, 2021.
-
aTyr Pharma to Participate in Piper Sandler Investor Lung Day
10/11/2021
aTyr Pharma, Inc. today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will participate in a fireside chat as part of the Piper Sandler Virtual Investor Day: Developing Therapeutics for Lung Indications on Friday, October 15, 2021, at 9:00am ET / 6:00am PT.
-
BioSpace Movers & Shakers, Oct. 8
10/8/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
aTyr Pharma Announces Appointment of Robert W. Ashworth, PhD, as Vice President of Regulatory Affairs
10/6/2021
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Robert W. Ashworth, Ph.D., to Vice President, Regulatory Affairs.
-
aTyr Pharma Announces Poster Presentation at the Society for Immunotherapy of Cancer Annual Meeting
10/1/2021
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will present a poster at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting,
-
Clinical Catch-Up: September 13-17
9/20/2021
With a conference the size of ESMO, it’s impossible to cover all the exciting news, but here are many of the highlights. Here’s a look. -
aTyr Pharma Announces Closing of $86.3 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
9/20/2021
aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the closing of an underwritten public offering of 10,781,250 shares of its common stock at a public offering price of $8.00 per share, which included the full exercise of the underwriters’ option to purchase additional shares.
-
aTyr Pharma to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
9/16/2021
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview at the virtual Oppenheimer Fall Healthcare Life Sciences and MedTech Summit,
-
aTyr Pharma Announces Pricing of $75 Million Public Offering of Common Stock
9/16/2021
aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the pricing of an underwritten public offering of 9,375,000 shares of its common stock at a public offering price of $8.00 per share.
-
aTyr Pharma Announces Proposed Public Offering of Common Stock - Sep 15, 2021
9/15/2021
aTyr Pharma, Inc., a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, announced that it has commenced an underwritten public offering of shares of its common stock.
-
aTyr Pharma Announces Positive Data from Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response for ATYR1923 in Pulmonary Sarcoidosis
9/13/2021
aTyr Pharma, Inc. today announced positive results from its Phase 1b/2a double-blind, placebo-controlled clinical trial of its lead therapeutic candidate, ATYR1923
-
aTyr Pharma Announces Expansion of Research Collaboration with The Ohio State University
8/10/2021
aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company, today announced that the company has expanded its research collaboration with The Ohio State University (OSU) to deepen the understanding of the immune mechanisms of sarcoid granuloma formation and identify potential biomarkers of efficacy for the company’s lead therapeutic candidate, ATYR1923, which is currently in clinical development for the treatment of pulmonary sarcoidosis.
-
aTyr Pharma Announces Two Abstracts for ATYR1923 Accepted for Presentation at the European Respiratory Society International Congress
8/9/2021
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that two abstracts for the company’s lead therapeutic candidate, ATYR1923, have been accepted for presentation at the 2021 European Respiratory Society International Congress to be held virtually September 5 – 8.
-
aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2021 Financial Results
8/3/2021
aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, announced that it will report second quarter 2021 financial results and provide a corporate update after the market close on Tuesday, August 10, 2021.
-
aTyr Pharma Announces Grant of U.S. Patent for Use of Histidyl-tRNA Synthetase Fc Fusion Proteins for Reducing Inflammatory Response in the Lung
7/29/2021
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the U.S. Patent and Trademark Office (USPTO) has granted a patent covering methods for the use of histidyl-tRNA synthetase Fc fusion proteins for reducing inflammatory response in the lung.
-
aTyr Pharma Announces Last Patient Visit in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis
7/8/2021
aTyr Pharma, Inc. today announced that the last patient has completed their last visit in the company’s Phase 1b/2a clinical trial of its lead therapeutic candidate, ATYR1923, in patients with pulmonary sarcoidosis.
-
aTyr Pharma to Host Virtual Key Opinion Leader Event on Current Treatment Options for Pulmonary Sarcoidosis
6/23/2021
aTyr Pharma, Inc. today announced that the company will host a virtual Key Opinion Leader (KOL) event on the current treatment options for pulmonary sarcoidosis on Tuesday, June 29th at 5:00pm ET/2:00pm PT.
-
aTyr Pharma Presents Poster Demonstrating Functional Selectivity of Second Anti-NRP2 Antibody
6/10/2021
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the presentation of a poster at the Antibody Engineering & Therapeutics Europe Virtual conference which was held June 8 – 10, 2021
-
Kezar Life Sciences Announces Formation of Clinical Advisory Committee
6/8/2021
Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, announced the formation of its Clinical Advisory Committee.
-
aTyr Pharma Strengthens Board of Directors with Appointment of Dr. Sara Zaknoen
5/25/2021
aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, announced the appointment of Sara Zaknoen, M.D., to the company’s Board of Directors.